Abstract
Lymphomas are a large, heterogeneous group of neoplasms with well-defined characteristics, and this heterogeneity highlights the importance of epidemiological data. Knowledge of local epidemiology is essential to optimise resources, design clinical trials, and identify minority entities. Given there are few published epidemiological data on lymphoma in Spain, the Spanish Lymphoma and Autologous Bone Marrow Transplant Group created the RELINF project. The aim of this project is to determine the frequencies and distribution of lymphoid neoplasms in Spain and to analyse survival. We developed an online platform for the prospective collection of data on newly diagnosed cases of lymphoma in Spain between January 2014 and July 2018; 11,400 patients were registered. Diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) were the most frequent lymphomas in our series. Marginal B cell lymphoma frequency was higher than that reported in other studies, representing more than 11% of mature B cell lymphomas. Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) was the most common subtype of T cell lymphoma, and NK/T cell lymphomas were more frequent than expected (5.4% of total). Hodgkin’s lymphoma accounted for 12% of lymphoproliferative syndromes. Overall survival was greater than 90% at 2 years for indolent B cell lymphomas, and approximately 60% for DLBCL, somewhat lower than that previously reported. Survival was poor for PTCL-NOS and angioimmunoblastic T cell lymphoma, as expected; however, it was somewhat better than that in other studies for anaplastic large cell anaplastic lymphoma kinase lymphomas. This is the first prospective registry to report the frequencies, distribution, and survival of lymphomas in Spain. The frequencies and survival data we report here are globally consistent with that reported in other Western countries. These updated frequencies and survival statistics are necessary for developing appropriate management strategies for neoplasias in the Spanish population.
Similar content being viewed by others
References
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390
(1982) National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The non-Hodgkin’s lymphoma pathologic classification project. Cancer 49(10):2112–2135
Lenz G, Staudt LM (2010) Aggressive lymphomas. N Engl J Med 362(15):1417–1429
Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma E-J, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project (2006) Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 354(23):2431–2442
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351(21):2159–2169
Sant M, Allemani C, De Angelis R, Carbone A, de Sanjosè S, Gianni AM et al (2008) Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 44(4):579–587
Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J et al (2003) EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. Ann Oncol 14(Suppl 5):v61–v118
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386
Wright F, Hapgood G, Loganathan A, Dunn N, Philpot S, Moore J, Mollee P (2018) Relative survival of patients with lymphoma in Queensland according to histological subtype. Med J Aust 209(4):166–172
Tomoka T, Montgomery ND, Powers E, Dhungel BM, Morgan EA, Mulenga M et al (2018) Lymphoma and pathology in sub-Saharan Africa: current approaches and future directions. Clin Lab Med 38(1):91–100
Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, Tomotaka S, Morton LM, Weisenburger DD, Matsuo K (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164(4):536–545
Yuan Y, Yang L, Sun T, Li H, Zhu J, Song Y, Wang N (2014) Analysis of lymphoma incidence in Beijing, 1998-2010. Zhonghua Yu Fang Yi Xue Za Zhi 48(8):669–673
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 107(1):265–276
Marcos-Gragera R, Cervantes-Amat M, Vicente ML, de Sanjosé S, Guallar E, Godoy C, Calvo C, Giraldo P, Sant M, Peris-Bonet R, Carmen Martos M (2010) Population-based incidence of childhood leukaemias and lymphomas in Spain (1993-2002). Eur J Cancer Prev 19(4):247–255
Rodríguez-García JA, Vázquez L, Ramos F, Cuevas B, Martín A, Smucler A et al (2015) Incidence of haematological neoplasms in Castilla y León, Spain. Med Clin (Barc) 144(11):491–500
Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O et al (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 116(19):3724–3734
Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, Patmore R, Jack A, Roman E (2015 Apr 28) Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK’s haematological malignancy research network. Br J Cancer 112(9):1575–1584
Dandoit M, Mounier M, Guy J, Petrella T, Girard S, Casasnovas R-O, Martin L, Bonnetain F, Maynadié M (2015) The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry. Leuk Lymphoma 56(4):1050–1057
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443
Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M, Boilesen E, Armitage JO, Weisenburger DD (2016) Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project. Haematologica. 101(10):1244–1250
(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood. 89(11):3909–3918
Khalil MO, Morton LM, Devesa SS, Check DP, Curtis RE, Weisenburger DD et al (2014) Incidence of marginal zone lymphoma in the United States, 2001–2009 with a focus on primary anatomic site. Br J Haematol 165(1):67–77
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM (2014) Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 25(11):2211–2217
Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M, Otto B, Barrionuevo C, Baiocchi RA, Rochford R, Porcu P (2016 Dec) Extranodal NK/T-cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in north American and European cases. Curr Hematol Malig Rep 11(6):514–527
Barrionuevo C, Zaharia M, Martinez MT, Taxa L, Misad O, Moscol A et al (2007) Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol 15(1):38–44
Au W, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim W-S, Sng I, Vose J, Armitage JO, Liang R, International Peripheral T-Cell Lymphoma Project (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-cell lymphoma project. Blood. 113(17):3931–3937
Treviño A, Alcantara LC, Benito R, Caballero E, Aguilera A, Ramos JM et al (2014) Molecular epidemiology and clinical features of human T cell lymphotropic virus type 1 infection in Spain. AIDS Res Hum Retrovir 30(9):856–862
de Mendoza C, Caballero E, Aguilera A, Requena S, de Lejarazu RO, Pirón M et al (2017) Human T-lymphotropic virus type 1 infection and disease in Spain. AIDS 31(12):1653–1663
Siegel RL, Miller KD, Jemal A (2018 Jan) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30
Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339(21):1506–1514
Klimm B, Goergen H, Fuchs M, von Tresckow B, Böll B, Meissner J et al (2013) Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann Oncol 24(12):3070–3076
Böll B, Görgen H (2019) The treatment of older Hodgkin lymphoma patients Br J Haematol 184(1):82–92
Frederiksen JK, Sharma M, Casulo C, Burack WR (2015) Systematic review of the effectiveness of fine-needle aspiration and/or core needle biopsy for subclassifying lymphoma. Arch Pathol Lab Med 139(2):245–251
Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 377(9759):42–51
Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A et al (2017) Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood 130(15):1772–1774
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242
Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G, German High-Grade Non-Hodgkin Lymphoma Study Group (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 121(12):2253–2263
Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, Lipscomb J, Flowers CR (2011) Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 117(11):2530–2540
Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Brière J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood. 92(1):76–82
Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, Harris NL, Jaffe ES, Pileri SA, Savage KJ, Weisenburger DD, Armitage JO, Mounier N, Vose JM (2013) Clinicopathologic characteristics of angioimmunoblastic T cell lymphoma: analysis of the international peripheral T cell lymphoma project. J Clin Oncol 31(2):240–246
Sibon D, Fournier M, Brière J, Lamant L, Haioun C, Coiffier B, Bologna S, Morel P, Gabarre J, Hermine O, Sonet A, Gisselbrecht C, Delsol G, Gaulard P, Tilly H (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 30(32):3939–3946
Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A (2017) Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials. J Clin Oncol 35(18):1999–2007
Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B (2017) Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 5:CD007941
Nogová L, Reineke T, Josting A, Müller-Hermelink HK, Eich HT, Behringer K et al (2005) Lymphocyte-predominant and classical Hodgkin’s lymphoma--comparison of outcomes. Eur J Haematol Suppl 66:106–110
Tanimura A, Hirai R, Nakamura M, Takeshita M, Hagiwara S, Miwa A (2018) The prognostic impact of dose-attenuated R-chop therapy for elderly patients with diffuse large B-cell lymphoma. Intern Med 57:3521
Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A (2013) Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14(6):525–533
Acknowledgements
The authors would like thank Dr. Pascual Balsalobre and José María Bellon, for their contribution to the statistical analysis; Angel Cedillo and Mónica Sanchez, for their dedication and effort to initiate and keep the project active; to all the GELTAMO group members, for their involvement with the project; and to Dr. Jorge Gayoso, my mentor and friend, who suggested I carry out this project.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Animal studies
This article does not contain any studies using animals performed by any of the authors.
Informed consent
Informed consent was not obtained from the individual participants included in the study because the local ethics committee approved its omission, given the registry is completely anonymised and does not include personal patient data beyond age and sex or treatments administered.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bastos-Oreiro, M., Muntañola, A., Panizo, C. et al. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. Ann Hematol 99, 799–808 (2020). https://doi.org/10.1007/s00277-020-03918-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-03918-6